insights_auto
Outlook: 53.8% bullish·0.0% bearish
Go to analysischevron_right
BDX:NYSE
Becton Dickinson and Co
$182.75
arrow_upward
+1.44%(+2.59) 1D
$182.75
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 8, 4:00:04 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BDX...
Open
$179.76
High
$182.76
Low
$178.90
Mkt. cap
49.78B
Avg. vol.
1.79M
Volume
1.52M
Dividend
2.30%
Quarterly dividend
$1.05
Ex-dividend date
Sep 9, 2026
P/E ratio
55.20
52-wk high
$193.07
52-wk low
$127.54
EPS
$3.31
Beta
0.21
Shares outstanding
272.39M
No. of employees
72K
Open
$179.76
High
$182.76
Low
$178.90
Mkt. cap
49.78B
Avg. vol.
1.79M
Volume
1.52M
Dividend
2.30%
Quarterly dividend
$1.05
Ex-dividend date
Sep 9, 2026
P/E ratio
55.20
52-wk high
$193.07
52-wk low
$127.54
EPS
$3.31
Beta
0.21
Shares outstanding
272.39M
No. of employees
72K
News stories
From web sources and news partners
News Corp
·
4 hours ago
Becton Dickinson & Co. stock outperforms competitors on strong trading day
MarketWatch
·
4 hours ago
Becton Dickinson & Co. stock outperforms competitors on strong trading day
Profile
Becton, Dickinson and Company is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.
BD is ranked #211 in the 2024 Fortune 500 list based on its revenues for the fiscal year ending September 30, 2023. Wikipedia
About Becton Dickinson and Co
CEOThomas Polen
Employees72K
Founded1897
HeadquartersFranklin Lakes, New Jersey, United States
SectorMedical device
Websitebd.com
Analyst ratings
Based on 10 analysts giving stock ratings to BDX in the past 3 months
Buy
Buy
4
Hold
5
Sell
1
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for BDX in the last 3 months.
Highest
Current $182.75
$210.00 (+14.91%)
Average
$191.80 (+4.95%)
Lowest
$165.00 (-9.71%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Travis Steed Bank of America Securities | Hold | Maintained | $200.00 | +9.4% | 10/06/2026 |
Christopher Pasquale Barclays | Sell | Initiated | $165.00 | -9.7% | 10/07/2026 |
Matt Miksic Barclays | Sell | Maintained | $165.00 | -9.7% | 10/07/2026 |
Joanne Wuensch Citi | Buy | Maintained | $208.00 | +13.8% | 10/05/2026 |
Kendall Au RBC Capital | Hold | Maintained | $190.00 | +4% | 10/01/2026 |
Matthew Taylor Jefferies | Buy | Maintained | $210.00 | +14.9% | 09/08/2026 |
Josh Jennings TD Cowen | Hold | Reiterated | $182.00 | -0.4% | 08/17/2026 |
Patrick Wood UBS | Buy | Reiterated | $205.00 | +12.2% | 08/12/2026 |
Robbie Marcus J.P. Morgan | Hold | Maintained | $188.00 | +2.9% | 08/10/2026 |
Rick Wise Stifel Nicolaus | Buy | Maintained | $195.00 | +6.7% | 08/11/2026 |
Jason Bednar Piper Sandler | Hold | Reiterated | $175.00 | -4.2% | 08/07/2026 |
Shagun Singh Chadha RBC Capital | Hold | Maintained | $180.00 | -1.5% | 08/06/2026 |
Vijay Kumar Evercore ISI | Buy | Maintained | $180.00 | -1.5% | 07/06/2026 |
David Roman Goldman Sachs | Hold | Initiated | $167.00 | -8.6% | 04/10/2026 |
David Toung Argus Research | Buy | Reiterated | $180.00 | -1.5% | 03/20/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $190.00 | +4% | 02/10/2026 |
Unknown Analyst J.P. Morgan | Hold | Maintained | $175.00 | -4.2% | 02/10/2026 |
Larry Biegelsen Wells Fargo | Hold | Maintained | $157.00 | -14.1% | 02/10/2026 |
Last report
Aug 6, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$3.23 / $3.14
+2.93%beat
arrow_upward
Revenue / Est. (USD)
4.98B / 4.89B
+1.91%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 5.89B | 4.49B | 4.71B | 4.98B |
Cost of goods sold | 3.09B | 2.43B | 2.56B | 2.67B |
Cost of revenue | 3.09B | 2.43B | 2.56B | 2.67B |
Research and development expenses | 322.00M | 235.00M | 249.00M | 258.00M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.43B | 1.23B | 1.24B | 1.27B |
Operating expense | 1.75B | 1.46B | 1.46B | 1.53B |
Total operating expenses | 4.84B | 3.90B | 4.02B | 4.20B |
Operating income | 1.05B | 590.00M | 695.00M | 784.00M |
Other non operating income | 92.00M | -12.00M | 109.00M | 30.00M |
EBT including unusual items | 510.00M | 311.00M | 39.00M | 553.00M |
EBT excluding unusual items | 947.00M | 429.00M | 664.00M | 686.00M |
Income tax expense | 17.00M | - | 76.00M | 102.00M |
Effective tax rate | 3.33% | - | 194.87% | 18.44% |
Other operating expenses | -4.00M | 1.00M | -26.00M | - |
Net income | 493.00M | 383.00M | -311.00M | 377.00M |
Net profit margin | 8.37% | 8.54% | -6.60% | 7.57% |
Earnings per share | 3.96 | 2.91 | 2.90 | 3.23 |
Interest and investment income | 5.00M | 4.00M | 9.00M | 4.00M |
Interest expense | -155.00M | -153.00M | -149.00M | -132.00M |
Net interest expenses | -150.00M | -149.00M | -140.00M | -128.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 1.68B | 1.20B | 1.22B | 1.35B |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1